Soleno Therapeutics has started a Phase III clinical trial of Diazoxide Choline Controlled-Release (DCCR) tablet for the treatment of patients with Prader-Willi Syndrome (PWS).

The randomised, placebo-controlled trial will enrol around 100 PWS patients at 10-15 sites in the US.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Seattle Children’s Hospital in the US is the first site to be activated for the trial, which is expected to be completed over a period of nine to 12 months.

Soleno has appointed Dr Parisa Salehi as the Principal Investigator for the trial at the Seattle Children’s Hospital site.

“There is a lack of effective medical therapy targeting hunger in this population, and such a drug would be life-altering.”

Salehi said: “Prader-Willi Syndrome leads to hyperphagia that can cause life-threatening obesity if left uncontrolled.

“This excessive hunger can cause significant harm to the lives of these individuals and their families. There is a lack of effective medical therapy targeting hunger in this population, and such a drug would be life-altering.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“Based on the data generated to date, DCCR has the potential to address this treatment void.”

DCCR is a new, extended-release, crystalline salt formulation of diazoxide, which is given once-daily to the patients and has been used for ages for treating patients suffering from a few rare diseases in neonates, infants, children and adults.

The tablet, however, has not been approved for use in PWS.

According to Prader-Willi Syndrome Association USA, one in 12,000 to 15,000 people in the US is estimated to have PWS, which leads to hyperphagia, a chronic feeling of insatiable hunger that significantly reduces the quality of life for PWS patients and their families.